Topoisomerase II inhibitor 18, identified by its CAS number 2382959-65-9, is a synthetic compound that functions primarily as an inhibitor of the enzyme topoisomerase II. This enzyme plays a crucial role in DNA replication and transcription by managing the topology of DNA, particularly during processes that involve the unwinding and rewinding of DNA strands. Inhibition of topoisomerase II can lead to the disruption of DNA replication and ultimately induce apoptosis in rapidly dividing cells, making such inhibitors of interest in cancer therapy. The compound is characterized by its specific molecular structure, which typically includes functional groups that enhance its binding affinity to the enzyme's active site. Additionally, it may exhibit properties such as solubility in organic solvents, moderate to high molecular weight, and potential cytotoxic effects on various cancer cell lines. As with many pharmacological agents, the efficacy and safety profile of Topoisomerase II inhibitor 18 would be evaluated through preclinical and clinical studies to determine its therapeutic potential and side effects.

Topoisomerase II inhibitor 18

2382959-65-9: Topoisomerase II inhibitor 18, identified by its CAS number 2382959-65-9, is a synthetic compound that functions primarily as an inhibitor of the enzyme topoisomerase II. This enzyme plays a crucial role in DNA replication and transcription by managing the topology of DNA, particularly during processes that involve the unwinding and rewinding of DNA strands. Inhibition of topoisomerase II can lead to the disruption of DNA replication and ultimately induce apoptosis in rapidly dividing cells, making such inhibitors of interest in cancer therapy. The compound is characterized by its specific molecular structure, which typically includes functional groups that enhance its binding affinity to the enzyme's active site. Additionally, it may exhibit properties such as solubility in organic solvents, moderate to high molecular weight, and potential cytotoxic effects on various cancer cell lines. As with many pharmacological agents, the efficacy and safety profile of Topoisomerase II inhibitor 18 would be evaluated through preclinical and clinical studies to determine its therapeutic potential and side effects.

<p>Topoisomerase II inhibitor 18 (Compound IV), a Quinoxaline derivative, exhibits an IC 50 of 7.5 μM in inhibiting topoisomerase II. It impedes PC-3 cell proliferation, arrests the cell cycle at the S phase, and induces apoptosis. Moreover, this compound demonstrates substantial antitumor activity against cancer [1].</p>

CAS 2382959-65-9

Topoisomerase II inhibitor 18

Topoisomerase II inhibitor 18

Ref: TM-T87552